“Photodynamic therapy (PDT) is not just a palliative treatment,” declared Patrick Ross, Jr, MD, PhD, Director, Division of Thoracic Surgery, The Ohio State University (OSU), Columbus, Ohio. “The real bang for the buck with PDT has got to be curative attempt.” PDT first emerged on the scene at OSU primarily as an effective palliative tool for symptom management in patients with advanced non–small cell lung cancer (NSCLC), with very few complications. Now many researchers and clinicians are considering the role of PDT for curative indications, such as primary treatment of early airway cancer and induction therapy in combination with other modalities. This article offers a backward glance at the early results with PDT at OSU since 1998, a contemporary look at the various indications for PDT in treating airway malignancies, and a future perspective on the next steps for PDT as it moves forward.
McCaughan JS Jr, Ellison EC, Guy JT et al.. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg 1996;62:1005–1010.
McCaughan JS Jr, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg 1997;114:940–947.
Kiani B, Magro CM, Porcu P et al.. Polypoid endobronchial Hodgkin lymphoma with an initial response to photodynamic therapy. Ann Thorac Surg 2003;76:940–942.
Magro CM, Abbas AE, Ross P Jr. The application of photodynamic therapy in the treatment of metastatic endobronchial disease. Lasers Surg Med 2006;38:376–383.
Ross P Jr, Grecula J, Bekaii-Saab T et al.. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg Med 2006;38:881–889.
Kato H, Konaka C, Kawate N et al.. Five-year disease-free survival of a lung cancer patient treated only by photodynamic therapy. Chest 1986;90:768–770.